Thyrocare Technologies Limited

BSE:539871 Stock Report

Market Cap: ₹75.0b

Thyrocare Technologies Valuation

Is 539871 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 539871 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 539871 (₹471.15) is trading above our estimate of future cash flow value (₹321.12)

Significantly Below Future Cash Flow Value: 539871 is trading above our estimate of future cash flow value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 539871?

Key metric: As 539871 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 539871. This is calculated by dividing 539871's market cap by their current earnings.
What is 539871's PE Ratio?
PE Ratio46x
Earnings₹1.63b
Market Cap₹74.99b

Price to Earnings Ratio vs Peers

How does 539871's PE Ratio compare to its peers?

The above table shows the PE ratio for 539871 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average62.9x
METROPOLIS Metropolis Healthcare
59x21.60%₹112.1b
NEPHROPLUS Nephrocare Health Services
82x40.56%₹58.5b
VIJAYA Vijaya Diagnostic Centre
75.5x21.85%₹130.7b
526783 Dr. Agarwal's Eye Hospital
35.2xn/a₹24.6b
539871 Thyrocare Technologies
46x18.92%₹75.0b

Price-To-Earnings vs Peers: 539871 is good value based on its Price-To-Earnings Ratio (46x) compared to the peer average (62.9x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does 539871's PE Ratio compare vs other companies in the IN Healthcare Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
543500 Evoq Remedies
4.6xn/aUS$856.89k
No more companies available in this PE range
539871 46.0xIndustry Avg. 40.0xNo. of Companies11PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 539871 is expensive based on its Price-To-Earnings Ratio (46x) compared to the Indian Healthcare industry average (40x).

Price to Earnings Ratio vs Fair Ratio

What is 539871's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

539871 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio46x
Fair PE Ratio42.5x

Price-To-Earnings vs Fair Ratio: 539871 is expensive based on its Price-To-Earnings Ratio (46x) compared to the estimated Fair Price-To-Earnings Ratio (42.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 539871 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹471.15
₹595.00
+26.29%
7.91%₹650.00₹535.00n/a3
May ’27₹400.55
₹571.67
+42.72%
8.46%₹640.00₹535.00n/a3
Apr ’27₹361.35
₹571.67
+58.20%
8.46%₹640.00₹535.00n/a3
Mar ’27₹394.75
₹571.67
+44.82%
8.46%₹640.00₹535.00n/a3
Feb ’27₹400.20
₹571.67
+42.85%
8.46%₹640.00₹535.00n/a3
Jan ’27₹447.95
₹551.11
+23.03%
11.78%₹640.00₹486.67n/a3
Dec ’26₹485.65
₹506.67
+4.33%
3.95%₹526.67₹486.67n/a2
Nov ’26₹465.53
₹506.67
+8.84%
3.95%₹526.67₹486.67n/a2
Oct ’26₹382.93
₹451.67
+17.95%
7.75%₹486.67₹416.67n/a2
Sep ’26₹429.78
₹451.67
+5.09%
7.75%₹486.67₹416.67n/a2
Aug ’26₹441.10
₹451.67
+2.40%
7.75%₹486.67₹416.67n/a2
Jul ’26₹324.95
₹335.83
+3.35%
0.74%₹338.33₹333.33n/a2
Jun ’26₹350.12
₹335.83
-4.08%
0.74%₹338.33₹333.33n/a2
May ’26₹292.47
₹335.83
+14.83%
0.74%₹338.33₹333.33₹400.552
Apr ’26₹240.30
₹326.67
+35.94%
7.14%₹350.00₹303.33₹361.352
Mar ’26₹229.47
₹326.67
+42.36%
7.14%₹350.00₹303.33₹394.752
Feb ’26₹266.02
₹326.67
+22.80%
7.14%₹350.00₹303.33₹400.202
Jan ’26₹307.37
₹335.83
+9.26%
3.23%₹346.67₹325.00₹447.952
Dec ’25₹333.27
₹335.83
+0.77%
3.23%₹346.67₹325.00₹485.652
Nov ’25₹308.67
₹335.83
+8.80%
3.23%₹346.67₹325.00₹465.532
Oct ’25₹275.75
₹266.67
-3.29%
3.13%₹275.00₹258.33₹382.932
Sep ’25₹288.30
₹266.67
-7.50%
3.13%₹275.00₹258.33₹429.782
Aug ’25₹272.68
₹266.67
-2.21%
3.13%₹275.00₹258.33₹441.102
Jul ’25₹216.87
₹246.67
+13.74%
1.35%₹250.00₹243.33₹324.952
Jun ’25₹204.08
₹246.67
+20.87%
1.35%₹250.00₹243.33₹350.122
May ’25₹214.60
₹242.50
+13.00%
0.34%₹243.33₹241.67₹292.472
₹595
Fair Value
20.8% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/14 00:07
End of Day Share Price 2026/05/14 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Thyrocare Technologies Limited is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alka Katiyar360 ONE Capital Market Private Limited
Rahul AgarwalCGS International
Kameswari V. S. ChavaliFirstCall Research